Charles Conway - Nov 23, 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd. (BHVN)

Role
Chief Scientific Officer
Signature
/s/ Jim Engelhart, Attorney-in-Fact
Stock symbol
BHVN
Transactions as of
Nov 23, 2021
Transactions value $
$393,799
Form type
4
Date filed
11/26/2021, 03:26 PM
Previous filing
Nov 26, 2021
Next filing
Jan 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $375K +10K +166.33% $37.54* 16K Nov 23, 2021 Direct
transaction BHVN Common Shares Options Exercise $18.4K +885 +5.53% $20.79* 16.9K Nov 23, 2021 Direct
transaction BHVN Common Shares Options Exercise $0 +3K +17.75% $0.00 19.9K Nov 25, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -10K -100% $0.00* 0 Nov 23, 2021 Common Shares 10K $37.54 Direct F1
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -885 -2.08% $0.00 41.7K Nov 23, 2021 Common Shares 885 $20.79 Direct F2
transaction BHVN Restricted Share Unit Award Options Exercise $0 -3K -50% $0.00 3K Nov 25, 2021 Common Shares 3K Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vested in four equal installments on September 5, 2018, 2019, 2020 and 2021.
F2 The shares underlying this option vest in four equal installments on December 7, 2018, 2019, 2020 and 2021, subject to the reporting person's continued service with the issuer at each vesting date.
F3 Each restricted share unit represents the contingent right to receive one common share of the issuer.
F4 The reporting person was granted 12,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date.
F5 Not applicable.